Evidence map›Paper›PMID 41735739›Full record

ArticleMolecular imaging and biology2026

Value of Multitracer Imaging in Hepatocellular Carcinomas with Different Metastatic Potential.

Tingting He, Cong Zhang, Jinming Zhang, Xiaojun Zhang, Ruimin Wang

Abstract read
In one paragraph

Article in Molecular imaging and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tingting He *Beijing Universal Dicom Medical Imaging Diagnostic Center, Beijing, 100039, China.
Cong Zhang *Department of Nuclear Medicine, The First Medical Center, Chinese PLA General Hospital, Haidian District, No. 28 Fuxing Road, Beijing, 100853, China.
Jinming ZhangDepartment of Nuclear Medicine, The First Medical Center, Chinese PLA General Hospital, Haidian District, No. 28 Fuxing Road, Beijing, 100853, China.
Xiaojun ZhangDepartment of Nuclear Medicine, The First Medical Center, Chinese PLA General Hospital, Haidian District, No. 28 Fuxing Road, Beijing, 100853, China.
Ruimin WangDepartment of Nuclear Medicine, The First Medical Center, Chinese PLA General Hospital, Haidian District, No. 28 Fuxing Road, Beijing, 100853, China. wrm@yeah.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) shows marked heterogeneity and varying metastatic potential, challenging prognosis and treatment. This study evaluated multitracer PET imaging with [

methodsFour human HCC cell lines with varying metastatic potential (HepG2, QGY7701, MHCC97-H, MHCC97-L) were assessed for in vitro tracer uptake, proliferation, and invasion. Subcutaneous and spontaneous metastasis models were established in nude mice. Tumor uptake of tracers was quantified via microPET/CT. mRNA expression of MMP9 and VEGFR-2 and survival were analyzed. Fisher's classifier was applied to compare single-, dual-, and triple-tracer datasets with cross-validation.

resultsTracer uptake significantly differed among cell lines (p < 0.001). The triple-tracer model ([

conclusionsA multiparameter (multitracer) classification model had superior ability to discriminate four HCC cell lines with different biological behavior compared with dual tracers or single tracer through in vitro cell uptake experiment. [1⁸F]FDG uptake can distinguish between tumor models with high and low metastatic potential, and [1⁸F]FDG uptake can predict the survival time in metastatic models. [

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnimalsCell Line, TumorCell ProliferationDideoxynucleosidesFluorodeoxyglucose F18HumansMatrix Metalloproteinase 9MiceMice, NudeNeoplasm MetastasisPositron-Emission TomographyPositron Emission Tomography Computed TomographyVascular Endothelial Growth Factor Receptor-2DideoxynucleosidesFluorodeoxyglucose F18Matrix Metalloproteinase 9Vascular Endothelial Growth Factor Receptor-2[18F]ACE[18F]FDG[18F]FLTBiological heterogeneityHepatocellular carcinomaMetastasisPET imagingPrognostic marker

Identifiers

PMID41735739
PMCPMC13160993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.